Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.235
Neutral
RSI(14)
77.966
Buy
STOCH(KDJ)(9,3,3)
65.137
Buy
ATR(14)
6.305
Low Volatility
CCI(14)
173.961
Buy
Williams %R
21.686
Buy
TRIX(12,20)
1.494
Sell
StochRSI(14)
100.000
Overbought
Guardant Health Inc
GH105.420USD
+5.120+5.10%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
13.18BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Guardant Health Inc
Currency: USD Updated: 2025-11-21Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Guardant Health Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
25
analysts
Buy
Current Rating
97.661
Target Price
-2.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Guardant Health Inc Highlights
StrengthsRisks
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 64.39% year-on-year.
Undervalued
The company’s latest PE is -32.81, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 128.93M shares, decreasing 9.68% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 795.23K shares of this stock.
Financial Health
Currency: USD Updated: 2025-11-21The company's current financial score is 6.33, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 265.20M, representing a year-over-year increase of 38.50%, while its net profit experienced a year-over-year increase of 13.95%.
Score
Financials
6.07
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.49
Operational Efficiency
5.13
Growth Potential
6.86
Shareholder Returns
7.10
Guardant Health Inc's Company Valuation
Currency: USD Updated: 2025-11-21The company’s current valuation score is 7.26, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -32.81, which is -100.00% below the recent high of 0.00 and 0.00% above the recent low of -32.81.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 31/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-11-21The company’s current earnings forecast score is 8.64, which is higher than the Healthcare Equipment & Supplies industry's average of 7.75. The average price target for Guardant Health Inc is 100.00, with a high of 120.00 and a low of 48.21.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
25
analysts
Buy
Current Rating
97.661
Target Price
-2.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Guardant Health Inc
GH
25
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Dexcom Inc
DXCM
30
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
22
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-21The company’s current price momentum score is 9.66, which is higher than the Healthcare Equipment & Supplies industry's average of 7.14. Sideways: Currently, the stock price is trading between the resistance level at 120.94 and the support level at 78.96, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
99.464
Buy
MA10
97.929
Buy
MA20
93.125
Buy
MA50
74.938
Buy
MA100
64.203
Buy
MA200
54.323
Buy
Institutional Confidence
Currency: USD Updated: 2025-11-21The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.41. The latest institutional shareholding proportion is 100.07%, representing a quarter-over-quarter decrease of 6.99%. The largest institutional shareholder is The Vanguard, holding a total of 11.88M shares, representing 9.22% of shares outstanding, with 4.89% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Capital International Investors
Invesco Advisers, Inc.
Deep Track Capital LP
Two Sigma Investments, LP
Eventide Asset Management, LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-11-21The company’s current risk assessment score is 5.77, which is higher than the Healthcare Equipment & Supplies industry's average of 4.74. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.56
VaR
+6.49%
240-Day Maximum Drawdown
+28.23%
240-Day Volatility
+70.23%
Return
Best Daily Return
60 days
+27.87%
120 days
+27.87%
5 years
+27.87%
Worst Daily Return
60 days
-5.69%
120 days
-9.32%
5 years
-27.14%
Sharpe Ratio
60 days
+3.28
120 days
+3.35
5 years
+0.21
Risk Assessment
Maximum Drawdown
240 days
+28.23%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+6.59
3 years
+0.87
5 years
-0.08
Skewness
240 days
+2.09
3 years
+1.13
5 years
+0.28
Volatility
Realised Volatility
240 days
+70.23%
5 years
--
Standardised True Range
240 days
+2.78%
5 years
+3.00%
Downside Risk-Adjusted Return
120 days
+779.09%
240 days
+779.09%
Maximum Daily Upside Volatility
60 days
+76.93%
Maximum Daily Downside Volatility
60 days
+64.39%
Liquidity
Average Turnover Rate
60 days
+1.97%
120 days
+1.88%
5 years
--
Turnover Deviation
20 days
-100.00%
60 days
-100.00%
120 days
-100.00%
Peer Comparison
Healthcare Equipment & Supplies
Guardant Health Inc
GH
7.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
CSTL
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Guardant Health Inc?
The TradingKey Stock Score provides a comprehensive assessment of Guardant Health Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Guardant Health Inc’s performance and outlook.
How do we generate the financial health score of Guardant Health Inc?
To generate the financial health score of Guardant Health Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Guardant Health Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Guardant Health Inc.
How do we generate the company valuation score of Guardant Health Inc?
To generate the company valuation score of Guardant Health Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Guardant Health Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Guardant Health Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Guardant Health Inc.
How do we generate the earnings forecast score of Guardant Health Inc?
To calculate the earnings forecast score of Guardant Health Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Guardant Health Inc’s future.
How do we generate the price momentum score of Guardant Health Inc?
When generating the price momentum score for Guardant Health Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Guardant Health Inc’s prices. A higher score indicates a more stable short-term price trend for Guardant Health Inc.
How do we generate the institutional confidence score of Guardant Health Inc?
To generate the institutional confidence score of Guardant Health Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Guardant Health Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Guardant Health Inc.
How do we generate the risk management score of Guardant Health Inc?
To assess the risk management score of Guardant Health Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Guardant Health Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Guardant Health Inc.
